Skip to content

Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer

A Phase III Randomized Trial Between 5 Day 3 Weekly and Weekly Cisplatin Based Chemotherapy for Patients With Locally Advanced Cervical Cancer

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00548821
Enrollment
Unknown
Registered
2007-10-24
Start date
Unknown
Completion date
Unknown
Last updated
2008-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced Cervical Cancer

Brief summary

The primary aim of this research protocol is to compare if there is a difference in progression free survival between weekly versus 5-day 3 weekly cisplatin based chemotherapy regimen in women with locally advanced cervical cancer. The secondary aims are to compare quality of life assessment of patients and their carers as well as toxicity profiles both acute and late.

Interventions

DRUGCisplatin

Sponsors

National University Hospital, Singapore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* stage IB2-IVA , histological proven cervical carcinoma * no previous diagnosis of carcinoma * no prior history of chemotherapy or radiotherapy * ECOG less than or equal to 2 * Above 21 years old * medically fit for radical concurrent Cisplatin based chemotherapy and radiotherapy * Hemoglobin \>10g/dL * Adequate hematological, renal and hepatic function according to all of the following laboratory values: * Absolute neutrophil count ≥ 1.5 ×109/l * Platelets ≥ 100 ×109/l * Serum creatinine ≤ 1.5 times upper limit of laboratory normal * Total serum bilirubin ≤ 1.5 times upper limit of laboratory normal * ASAT(AST) or ALAT(ALT) ≤ 2.5 times upper limit of laboratory normal * Alkaline phosphatase of ≤ 2.5 times upper limit of laboratory normal

Exclusion criteria

* Age below 21 * Presence of known HIV infection, chronic hepatitis B or hepatitis C infection * Psychological, familial, sociological, or geographical condition that would preclude study participation * Prior (within the last 3 years) or simultaneous malignancies (other then cutaneous basal cell carcinoma or non-invasive tumors) * Patients with the following histologies are excluded: small cell, carcinoid, glassy cell, clear cell and adenoid cystic. * Life expectancy \< 6 months * Patients with insulin dependent diabetes * Prior tumor-directed surgery * Previous systemic chemotherapy or pelvic radiation therapy * As radiation and cytotoxic agents are contraindicated in pregnancy, pregnant women are ineligible and those of childbearing potential should use contraception

Design outcomes

Primary

MeasureTime frame
The primary aim of this research protocol is to compare if there is a difference in progression free survival between weekly versus 5-day 3 weekly cisplatin based chemotherapy regimen in women with locally advanced cervical cancer.

Secondary

MeasureTime frame
The secondary aims are to compare quality of life assessment of patients and their carers as well as toxicity profiles both acute and late.

Countries

Singapore

Contacts

Primary ContactJohann Tang
Johann_Tang@mail.nhg.com.sg677204870

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026